- Home
- OC vs EXEL Comparison
OC vs EXEL Comparison
Compare OC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OC | EXEL |
|---|---|---|
| Founded | 1938 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | OC | EXEL |
|---|---|---|
| Price | $113.75 | $44.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 24 |
| Target Price | ★ $157.33 | $44.73 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | ★ $11,659,000,000.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.14 |
| Revenue Next Year | N/A | $12.51 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | ★ 21.69 | 9.93 |
| 52 Week Low | $97.53 | $31.90 |
| 52 Week High | $203.68 | $49.62 |
Technical Indicators
Market Signals| Indicator | OC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 63.52 |
| Support Level | $97.53 | $43.00 |
| Resistance Level | $116.00 | $44.79 |
| Average True Range (ATR) | 3.75 | 1.03 |
| MACD | 2.16 | 0.06 |
| Stochastic Oscillator | 87.79 | 83.48 |
Price Performance
Historical ComparisonAbout OC Owens Corning Inc New
Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with four reportable segments: Composites, Insulation, Doors, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.